The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
PRIMO 2023 | Advances in the treatment of pancreatic cancer
Andrew Ko, MD, FASCO, University of California, San Francisco, CA, discusses the latest developments in the management of pancreatic cancer, including the Precision Promise (PrP) trial (NCT04229004) of multiple novel therapeutic options in metastatic pancreatic ductal adenocarcinoma (PDAC). Dr Ko additionally highlights the promising efficacy of pamrevlumab, adjuvant olaparib, and RNA vaccines. This interview took place at the Practical Recommendations in Immuno and Molecular Oncology (PRIMO) 2023 Congress in Honolulu, HI.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
